Effects of aging and a high fat diet on body weight and glucose tolerance in glucagon-like peptide-1 receptor -/- mice.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Endocrinology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1210/en.139.7.3127PMID 9645685
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular cloning of a cDNA encoding for the GLP-1 receptor expressed in rat lung.

  2009cited by this paper
• PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats.

  1998cited by this paper
• Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats.

  1998cited by this paper
• Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

  1998cited by this paper
• Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus.

  1997cited by this paper
• GLUT4 heterozygous knockout mice develop muscle insulin resistance and diabetes

  1997cited by this paper
• Low Plasma Leptin in Response to Dietary Fat in Diabetes- and Obesity-Prone Mice

  1997cited by this paper
• Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem.

  1997cited by this paper
• Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons.

  1996cited by this paper
• Phenotypes of Mouse diabetes and Rat fatty Due to Mutations in the OB (Leptin) Receptor

  1996cited by this paper
• Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

  1996cited by this paper
• Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene

  1996cited by this paper
• The Effect of Glucagon-Like Peptide I (GLP-I) on Glucose Elimination in Healthy Subjects Depends on the Pancreatic Glucoregulatory Hormones

  1996cited by this paper
• Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats.

  1996cited by this paper
• A role for glucagon-like peptide-1 in the central regulation of feeding

  1996cited by this paper
• Normalization of Insulin Responses to Glucose by Overnight Infusion of Glucagon-Like Peptide 1 (7–36) Amide in Patients With NIDDM

  1996cited by this paper
• Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM

  1996cited by this paper
• Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y

  1996cited by this paper
• Central infusions of leptin and GLP-1-(7-36) amide differentially stimulate c-FLI in the rat brain.

  1996cited by this paper
• Attenuation of the Obesity Syndrome of ob/ob Mice by the Loss of Neuropeptide Y

  1996cited by this paper
• Glucagon-like peptide-1 is a physiological incretin in rat.

  1995cited by this paper
• Ectopic expression of the agouti gene in transgenic mice causes obesity, features of type II diabetes, and yellow fur.

  1995cited by this paper
• Transgenic knockouts reveal a critical requirement for pancreatic beta cell glucokinase in maintaining glucose homeostasis.

  1995cited by this paper
• Tissue‐specific expression of the human receptor for glucagon‐like peptide‐I: brain, heart and pancreatic forms have the same deduced amino acid sequences

  1995cited by this paper
• The NSY mouse: a new animal model of spontaneous NIDDM with moderate obesity

  1995cited by this paper
• Reduction of the Incretin Effect in Rats by the Glucagon-Like Peptide 1 Receptor Antagonist Exendin (9–39) Amide

  1995cited by this paper
• Derivation of completely cell culture-derived mice from early-passage embryonic stem cells.

  1993cited by this paper
• Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor.

  1993cited by this paper
• Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37)

  1993cited by this paper
• Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1.

  1992cited by this paper
• Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells.

  1992cited by this paper
• Autoradiographic localization of receptors for glucagon-like peptide-1 (7-36) amide in rat brain.

  1992cited by this paper
• Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.

  1992cited by this paper
• Fat (fat) and tubby (tub): two autosomal recessive mutations causing obesity syndromes in the mouse.

  1990cited by this paper
• Proteins bound at adjacent DNA elements act synergistically to regulate human proenkephalin cAMP inducible transcription.

  1988cited by this paper
• Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line.

  1987cited by this paper
• Glucagon-like peptide-1 7-36: a physiological incretin in man.

  1987cited by this paper
• Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut

  1987cited by this paper
• Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.

  1987cited by this paper
• Cellular localization of proglucagon/glucagon‐like peptide I messenger RNAs in rat brain

  1986cited by this paper

• GLP-1 physiology and pharmacology along the gut-brain axis

  2026cites this paper
• Antiobesity medications in adult and pediatric obesity and metabolic dysfunction-associated steatotic liver disease.

  2025cites this paper
• The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review

  2025cites this paper
• G proteins of the G12 family expressed by POMC neurons regulate key metabolic functions

  2025cites this paper
• The role of GIPR in food intake control

  2025cites this paper
• GLP-1 and the Neurobiology of Eating Control: Recent Advances

  2025cites this paper
• GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management

  2024cites this paper
• Natural Phytochemicals as SIRT Activators—Focus on Potential Biochemical Mechanisms

  2023cites this paper
• The interplay between leptin, glucocorticoids, and GLP1 regulates food intake and feeding behaviour

  2023cites this paper
• High frequency of germline recombination in Nestin-Cre transgenic mice crossed with Glucagon-like peptide 1 receptor floxed mice

  2023cites this paper
• The Role of Resveratrol in Aging and Senescence: A Focus on Molecular Mechanisms.

  2023cites this paper
• Slow and steady wins the race: 25 years developing the GLP-1 receptor as an effective target for weight loss.

  2022cites this paper
• Hypertension Related to Obesity: Pathogenesis, Characteristics and Factors for Control

  2022cites this paper
• Intestinal Gpr17 deficiency improves glucose metabolism by promoting GLP-1 secretion

  2022cites this paper
• The Design and Optimization of Monomeric Multitarget Peptides for the Treatment of Multifactorial Diseases.

  2022cites this paper
• Sleeve Gastrectomy Improves High-Fat Diet–Associated Hepatic Steatosis Independent of the Glucagon-like-Petpide-1 Receptor in Rats

  2022cites this paper
• Glucagon‐like peptide‐1 (GLP‐1) signalling in the brain: From neural circuits and metabolism to therapeutics

  2021cites this paper
• GLP-1 physiology informs the pharmacotherapy of obesity

  2021cites this paper
• GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice.

  2021cites this paper
• Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms

  2020cites this paper
• Mechanisms of Aging and the Preventive Effects of Resveratrol on Age-Related Diseases

  2020cites this paper
• Pharmacological antagonism of the incretin system protects against diet-induced obesity

  2019cites this paper
• Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates.

  2019cites this paper
• Glucagon-like peptide 1 (GLP-1)

  2019cites this paper
• Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity.

  2019cites this paper
• Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism

  2018cites this paper
• GLP-1 acts on habenular avoidance circuits to control nicotine intake

  2017cites this paper
• Neuroprotective effects of phytosterol esters against high cholesterol-induced cognitive deficits in aged rat.

  2017cites this paper
• Central Control of Feeding Behavior by the Secretin, PACAP, and Glucagon Family of Peptides

  2017cites this paper
• Never Waste a Good Crisis: Confronting Reproducibility in Translational Research.

  2016cites this paper
• Reappraisal of GIP Pharmacology for Metabolic Diseases.

  2016cites this paper
• Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease.

  2015cites this paper
• Extrapancreatic Effect of Glucagon like Peptide-1

  2015cites this paper
• Incretins: Their physiology and application in the treatment of diabetes mellitus

  2014cites this paper
• A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents

  2014cites this paper
• Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

  2013cites this paper
• Role of Secretin Peptide Family and their Receptors in the Hypothalamic Control of Energy Homeostasis

  2013cites this paper
• Is there a place for incretin therapies in obesity and prediabetes?

  2013cites this paper
• Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1

  2013cites this paper
• GLP‐1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities

  2012cites this paper
• GLP-1 and energy balance: an integrated model of short-term and long-term control

  2011cites this paper
• Hyperphagia and Increased Fat Accumulation in Two Models of Chronic CNS Glucagon-Like Peptide-1 Loss of Function

  2011cites this paper
• Hypothalamic control of energy and glucose metabolism

  2011cites this paper
• Prebiotic fibres dose-dependently increase satiety hormones and alter Bacteroidetes and Firmicutes in lean and obese JCR:LA-cp rats

  2011cites this paper
• Investigating the effects of physiological bile acids on GLP-1 secretion and glucose tolerance in normal and GLP-1R-/- mice

  2011cites this paper
• Role of the glucagon-like-peptide-1 receptor in the control of energy balance.

  2010cites this paper
• Wechselwirkung zwischen anorektischen und orexigenen Neuropeptiden bei der Regulation der Nahrungsaufnahme

  2009cites this paper
• Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease.

  2009cites this paper
• Insulin Action in the Double Incretin Receptor Knockout Mouse

  2008cites this paper
• Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure.

  2007cites this paper
• Quantitative trait loci for carbohydrate and total energy intake on mouse chromosome 17: congenic strain confirmation and candidate gene analyses (Glo1, Glp1r).

  2007cites this paper
• Improvement of Glucose Tolerance and Hepatic Insulin Sensitivity by Oligofructose Requires a Functional Glucagon-Like Peptide 1 Receptor

  2006cites this paper
• The biology of incretin hormones.

  2006cites this paper
• Resveratrol improves health and survival of mice on a high-calorie diet

  2006cites this paper
• Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice.

  2005cites this paper
• Transgenic animal models for the study of adipose tissue biology.

  2005cites this paper
• Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors.

  2004cites this paper
• Physiology of GLP-1 - Lessons from Glucoincretin Receptor Knockout Mice

  2004cites this paper
• Glucagon-Like Peptide 1 Excites Hypocretin/Orexin Neurons by Direct and Indirect Mechanisms: Implications for Viscera-Mediated Arousal

  2004cites this paper
• Peptides that regulate food intake: glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats.

  2003cites this paper
• The glucagon-like peptides: a double-edged therapeutic sword?

  2003cites this paper
• Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

  2003cites this paper
• Control of body weight: a physiologic and transgenic perspective

  2003cites this paper
• Enhancing incretin action for the treatment of type 2 diabetes.

  2003cites this paper
• Cardiac function in mice lacking the glucagon-like peptide-1 receptor.

  2003cites this paper
• Saturated-fat diet induces moderate diabetes and severe glomerulosclerosis in hamsters

  2003cites this paper
• Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats.

  2002cites this paper
• Biological actions and therapeutic potential of the glucagon-like peptides.

  2002cites this paper
• The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease

  2002cites this paper
• Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4

  2002cites this paper
• Anti-obesity drugs: a critical review of current therapies and future opportunities.

  2001cites this paper
• Glucagon-like Peptide (GLP)-2 Action in the Murine Central Nervous System Is Enhanced by Elimination of GLP-1 Receptor Signaling*

  2001cites this paper
• KO's and organisation of peptidergic feeding behavior mechanisms.

  2001cites this paper
• Minireview: the glucagon-like peptides.

  2001cites this paper
• Promising New Approaches to the Management of Obesity

  2000cites this paper
• Transgenic study of energy homeostasis equation: implications and confounding influences

  2000cites this paper
• Transgenic approach to the study of body weight regulation.

  2000cites this paper
• Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice.

  2000cites this paper
• Sustained Expression of Exendin-4 Does Not Perturb Glucose Homeostasis, β-Cell Mass, or Food Intake in Metallothionein-Preproexendin Transgenic Mice*

  2000cites this paper
• Targeted gene disruption in endocrine research--the case of glucagon-like peptide-1 and neuroendocrine function.

  2000cites this paper
• Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action.

  2000cites this paper
• Effect of leptin on hypothalamic GLP-1 peptide and brain-stem pre-proglucagon mRNA.

  2000cites this paper
• The glucagon-like peptides.

  1999cites this paper
• Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice.

  1999cites this paper
• [New prospects in genetics of obesity].

  1999cites this paper